Literature DB >> 21108742

Toll-like receptor 1 gene polymorphisms in childhood IgA nephropathy: a case-control study in the Korean population.

J S Lee1, H-K Park, J-S Suh, W-H Hahn, S W Kang, H J Park, M J Kim, J-H Chung, B-S Cho.   

Abstract

Toll-like receptors (TLRs) are innate immune mediators that stimulate nuclear factor kappa B and the inflammatory cytokines. TLR1 is expressed in renal tubular epithelial cells when the kidney is injured, but the role of TLR1 gene in glomerulonephritis has not been clearly elucidated. We aimed to investigate the association of TLR1 polymorphisms with immunoglobulin A nephropathy (IgAN) in children. One hundred and ninety pediatric patients with biopsy-proven IgAN and 283 healthy control subjects were enrolled. Two single nucleotide polymorphisms of TLR1 gene [rs4833095 (missense, Asn248Ser) and rs5743557 (promoter, -414C/T)] were selected and genotyped by direct sequencing. For rs4833095, the C/T genotype in the codominant model (vs. the T/T genotype) [odds ratio (OR) = 2.11, 95% confidence interval (CI): 1.21-3.69, P = 0.009] and the genotype containing C allele (C/T and C/C) in the dominant model (vs. the T/T genotype) (OR = 1.97, 95% CI: 1.16-3.34, P = 0.012) were associated with an increased risk of IgAN. For rs5743557, the T/T genotype in the codominant model (vs. the C/C genotype) (OR = 1.74, 95% CI: 1.02-2.96, P = 0.041) appeared to be associated with IgAN risk. In haplotype analysis, the CT haplotype revealed an association with IgAN (codominant model, OR = 1.38, 95% CI: 1.06-1.80, P = 0.017; dominant model, OR = 1.76, 95% CI: 1.16-2.67, P = 0.008). After Bonferroni correction, the association of the genotypes of rs4833095 and the CT haplotype with IgAN risk remained significant. These findings suggest that TLR1 gene polymorphisms may affect IgAN susceptibility in Korean children.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21108742     DOI: 10.1111/j.1744-313X.2010.00978.x

Source DB:  PubMed          Journal:  Int J Immunogenet        ISSN: 1744-3121            Impact factor:   1.466


  6 in total

Review 1.  A systems view of genetics in chronic kidney disease.

Authors:  Benjamin J Keller; Sebastian Martini; John R Sedor; Matthias Kretzler
Journal:  Kidney Int       Date:  2011-10-19       Impact factor: 10.612

2.  Haplotype structure and positive selection at TLR1.

Authors:  Christopher Heffelfinger; Andrew J Pakstis; William C Speed; Allison P Clark; Eva Haigh; Rixun Fang; Mahohar R Furtado; Kenneth K Kidd; Michael P Snyder
Journal:  Eur J Hum Genet       Date:  2013-09-04       Impact factor: 4.246

3.  Toll-like receptor 1 polymorphisms and associated outcomes in sepsis after traumatic injury: a candidate gene association study.

Authors:  Callie M Thompson; Tarah D Holden; Gail Rona; Balaji Laxmanan; R Anthony Black; Grant E OʼKeefe; Mark M Wurfel
Journal:  Ann Surg       Date:  2014-01       Impact factor: 12.969

4.  TLR1 polymorphism rs4833095 as a risk factor for IgA nephropathy in a Chinese Han population: A case-control study.

Authors:  Jie Gao; Linting Wei; Jiali Wei; Ganglian Yao; Li Wang; Meng Wang; Xinghan Liu; Cong Dai; Tianbo Jin; Zhijun Dai; Rongguo Fu
Journal:  Oncotarget       Date:  2016-12-13

5.  Toll-Like Receptor Family Polymorphisms Are Associated with Primary Renal Diseases but Not with Renal Outcomes Following Kidney Transplantation.

Authors:  Mark C Dessing; Jesper Kers; Jeffrey Damman; Henri G D Leuvenink; Harry van Goor; Jan-Luuk Hillebrands; Bouke G Hepkema; Harold Snieder; Jacob van den Born; Martin H de Borst; Stephan J L Bakker; Gerjan J Navis; Rutger J Ploeg; Sandrine Florquin; Marc Seelen; Jaklien C Leemans
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

6.  TLR1 polymorphisms are significantly associated with the occurrence, presentation and drug-adverse reactions of tuberculosis in Western Chinese adults.

Authors:  Wu Peng; Hao Chen; Zhenzhen Zhao; Xuejiao Hu; Yi Zhou; Yingyu Li; Lian Yang; Xuemei Wang; Jiajia Song; Tangyuheng Liu; Qian Wu; Hao Bai; Xiaojun Lu; Jie Chen; Binwu Ying
Journal:  Oncotarget       Date:  2017-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.